| Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.). | lung, |
| Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression. | pancreatic, |
| p21Waf1/Cip1 revisited: oncogenic function in hepatocellular carcinoma. | liver, |
| We show that loss of Scrib and activated oncogenic KRas cooperate in vivo, resulting in more aggressive lung tumors | lung, |
| Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report. | lymphoma,sarcoma,lung, |
| [Kras oncogene and pancreatic cancer: thirty years after]. | pancreatic, |
| MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2. | colorectal, |
| Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis. | lung, |
| Sag is a Kras-cooperating oncogene that promotes lung tumorigenesis | lung, |
| in KRas(G12D)-driven lung cancer, Atg5-regulated autophagy accelerates tumour progression; however, autophagy also represses early oncogenesis, suggesting a link between deregulated autophagy and regulatory T cell controlled anticancer immunity. | lung, |
| Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer. | sarcoma,colorectal, |
| Our findings suggest that IL-8 expression is associated with certain clinicopathological features including age and is a potent prognostic marker in lung adenocarcinoma, especially in oncogenic KRAS-driven adenocarcinoma. | lung, |
| Results demonstrate that ERbeta1 decreases the survival of NSCLC cells by regulating oncogenic RAS signaling. | lung, |
| Expression of ras oncogene p21 protein in relation to regional spread of human breast carcinomas. | breast, |
| Inhibition of breast cancer metastasis suppressor 1 promotes a mesenchymal phenotype in lung epithelial cells that express oncogenic K-RasV12 and loss of p53. | breast,lung, |
| Rapid onset lung squamous cell carcinoma with prominent peritoneal carcinomatosis and an eosinophilic leukemoid reaction, with coexistence of the BRAF V600E and oncogenic KRAS G12A mutations: A case report. | lung, |
| Cooperativity of oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis. | pancreatic, |
| oncogenic K-ras and downregulated p16/INK4A in human pancreatic tumorigenesis | pancreatic, |
| Oncogenic KRAS upregulated mir31 in lung carcinogenesis. | lung, |
| study surveyed the ability of 12 different oncogenic KRAS mutations to induce pancreatic tumors in an in vivo tumorigenesis assay; results suggest the spectrum of KRAS mutations observed in human pancreatic cancer reflects selection based on variable tumorigenic capacities, including ability to activate MAPK/ERK signaling | pancreatic, |